BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 7.60 -0.18 (2.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.78 | 52 Week High | $10.98 | |||
| Open | $7.71 | 52 Week Low | $1.63 | |||
| Day High | $7.76 | P/E | N/A | |||
| Day Low | $7.52 | EPS | $-0.68 | |||
| Volume | 804,446 | |||||
